Abbott Laboratories (ABT) narrows 2024 earnings guidance, shares slip
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% as AI buildout costs, Fed rate outlook weigh
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Abbott Labs (ABT) PT Lowered to $125 at RBC Capital
April 18, 2024 6:19 AM EDTRBC Capital analyst Shagun Singh lowered the price target on Abbott Labs (NYSE: ABT) to $125.00 (from $128.00) while maintaining a Outperform rating.
The analyst comments "ABT delivered a Q1 Rev/EPS upside of $80MM/$0.03, respectively, and tightened its FY24 guidance range. Despite a strong Q1... More
Abbott's device sales drive profit beat, but shares fall as forecast disappoints
April 17, 2024 7:34 AM EDTBy Leroy Leo and Pratik Jain
(Reuters) -Abbott Laboratories beat Wall Street estimates for quarterly profit on Wednesday on robust sales of its medical devices, but the company's stock fell 3% in morning trading, signaling disappointment over its annual forecast.
Investor expectations around the performance of medical device makers have been heightened since last November after a resurgence in demand, as people, especially older adults, opted for medical procedures deferred during the pandemic.
Abbott forecast a full-year profit of... More
